Table 1 Baseline characteristics of renal transplant recipients with IgA nephropathy as underlying disease leading to TX and their donors in the study population

Median age at TX (years) [IQR]

48 [38, 60]

39 [30, 53]

50 [42, 61]

Female, N (%)

28 (17.4%)

10 (23.3%)

18 (15.3%)

Caucasian, N (%)

148 (91.9%)

37 (86%)

111 (94.1%)

History of prior kidney TX, N (%)

22 (13.7%)

7 (16.3%)

15 (12.7%)

 - hemodialysis

95 (59%)

25 (58.1%)

70 (59.3%)

 - peritoneal dialysis

28 (17.4%)

7 (16.3%)

21 (17.8%)

 - pre-emptive TX

38 (23.6%)

11 (25.6%)

27 (22.9%)

Immunosuppression immediate before TX, N (%)

18 (11.2%)

5 (11.6%)

13 (11%)

Median age at donation [IQR]

53 [42, 62]

49 [42, 58]

55 [42, 63]

Female donors, N (%)

85 (52.8%)

25 (58.1%)

60 (50.8%)

Living donation, N (%)

95 (59%)

26 (60.5%)

69 (58.5%)

 - from relatives

62 (65.3%)

17 (65.4%)

45 (65.2%)

 Early allograft dysfunction, N (%)

15 (9.3%)

2 (4.7%)

13 (11%)

 Median cold ischemia time (hours) [IQR]

2.1 [1.2, 9.8]

1.5 [1.1, 10.7]

2.2 [1.3, 9.1]

 Induction therapy with ATG/Thymoglobulin, N (%)

26 (16.1%)

8 (18.6%)

18 (15.3%)

 - TAC-based

135 (83.9%)

41 (95.3%)

94 (79.7%)

 - Others

26 (16.1%)

2 (4.7%)

24 (20.3%)

Presence of HLA antibodies, N (%)

74 (46%)

23 (53.5%)

51 (43.2%)

Presence of DSA, N (%)

20 (12.4%)

7 (16.3%)

13 (11%)

 - Class I

5 (25%)

1 (14.3%)

4 (30.8%)

 - Class II

11 (55%)

2 (28.6%)

9 (69.2%)

 - Class I + II

4 (20%)

4 (57.1%)

0 (0%)

HLA full match, N (%)

13 (8.1%)

3 (7%)

10 (8.5%)

Mean number of HLA A/B/DR mismatch [min, max]

3.8 [1, 6]

3.7 [1, 6]

3.8 [1, 6]

CMV high-risk constellation (D+/R-), N (%)

19 (11.8%)

6 (14%)

13 (11%)

Administration of RAAS blockade (ACE inhibitor, ARB), N (%)

55 (34.2%)

17 (39.5%)

38 (32.2%)